Cell Therapy News/Articles, page-10724

Speaking of pulling numbers from the air. There's rate of mortality from aGVHD for all transplant recipients, which starts out with a patient population that doesn't have aGVHD and may not get it. That would be relevant in studying a drug to prevent aGVHD. That, as opposed to starting with a population that already has aGVHD, and studying drugs to treat it. Then, you might be starting with a population that has steroid-resistant aGVHD, and trying to treat that. That's the Remestemcel-L study, where the base mortality is obviously much higher than the base mortality for a prophylactic study or one in which you might not have steroid-refractory aGVHD.

Might as well be comparing our Covid treatment with the mortality rate from ARDS for all people who get vaccines, which is incredibly low, since most of the patients won't even get Covid, much less ARDS.